Mark Mitton-Fry

Mark Mitton-Fry
Professional Website

Mark Mitton-Fry, PhD

Assistant Professor
Medicinal Chemistry and Pharmacognosy
Parks Hall
mitton-fry.1@osu.edu
(614) 292-1903

Professional Interests

Dr. Mitton-Fry’s research team is dedicated to inventing cures for multidrug-resistant bacterial infections. The lab uses the tools of synthetic medicinal chemistry to design and prepare innovative new molecules, and we collaborate broadly to evaluate their biological, pharmaceutical, and toxicological properties. Dr. Mitton-Fry also enjoys teaching students at all levels about antibacterial therapies.

Education

  • 2002, PhD, University of Colorado Boulder
  • 1996, BA, Carleton College

Journal Articles

  • Li, L.; Okumu, A. A.; Nolan, S.; English, A.; Vibhute, S.; Lu, Y.; Hervert-Thomas, K.; Seffernick, J. T.; Azap, L.; Cole, S. L.; Shinabarger, D.; Koeth, L. M.; Lindert, S.; Yalowich, J. C.; Wozniak, D. J.; Mitton-Fry, M. J. 1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition. ACS Infect Dis, 2019, 5, 1115-1128.
  • Li, L.; Okumu, A.; Dellos-Nolan, S.; Li, Z.; Karmahapatra, S.; English, A.; Yalowich, J. C.; Wozniak, D. J.; Mitton-Fry, M. J. Synthesis and Anti-staphylococcal activity of Novel Bacterial Topoisomerase Inhibitors with a 5-amino-1,3-dioxane Linker Moiety. Bioorg. Med. Chem. Lett. 2018, 28, 2477-2480.
  • Mitton-Fry, M. J.Novel bacterial type II topoisomerase inhibitors In Medicinal Chemistry Reviews, Vol. 52, Bronson, J., Ed.; American Chemical Society, 2017, pp. 281-302.
  • Li, L.; Okumu, A.; Dellos-Nolan, S.; Li, Z.; Karmahapatra, S.; English, A.; Yalowich, J. C.; Wozniak, D. J.; Mitton-Fry, M. J. Synthesis and Anti-staphylococcal activity of Novel Bacterial Topoisomerase Inhibitors with a 5-amino-1,3-dioxane Linker Moiety Bioorg. Med. Chem. Lett. 2018, 28, 2477-2480. DOI: 10.1016/j.bmcl.2018.06.003.
  • Lall, M. S.; Tao, Y.; Arcari, J. T.; Boyles, D.; Brown, M. F.; Damon, D. B.; Lilley, S. C.; Mitton-Fry, M. J.; Starr, J. T.; Stewart, A. M.; Sun, J. Process Development for the Synthesis of Monocyclic -Lactam Core 17. Org. Process Res. Dev. 2018, 22, 212-218, DOI: 10.1021/acs.oprd.7b00359.
  • Vazquez, M. L.; Kaila, N.; Strohbach, J. W.; Trzupek, J. D.; Brown, M. F.; Flanagan, M. E.; Mitton-Fry, M. J.; Johnson, T. A.; TenBrink, R. E.; Arnold, E. P.; Basak, A.; Heasley, S. E.; Kwon, S.; Langille, J.; Parikh, M. D.; Griffin, S. H.; Casavant, J. M.; Duclos, B. A.; Fenwick, A. E.; Harris, T. M.; Han, S.; Caspers, N.; Dowty, M. E.; Yang, X.; Banker, M. E.; Hegen, M.; Symanowicz, P. T.; Li, L.; Wang, L.; Lin, T. H.; Jussif, J.; Clark, J. D.; Telliez, J.-B.; Robinson, R. P.; Unwalla, R.; Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases. J. Med. Chem. 2018, 61, 1130-1152, DOI: 10.1021/acs.jmedchem.7b01598.
  • Linsen Li, Antony A. Okumu, Sheri Nolan, Anthony English, Sandip Vibhute, Yanran Lu, Katherine Hervert-Thomas, Justin T. Seffernick, Lovette Azap, Serena L. Cole, D. Shinabarger, Laura M. Koeth, Steffen Lindert , Jack C. Yalowich, Daniel J. Wozniak, and Mark J. Mitton-Fry1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition ACS Infect. Dis. 2019 DOI: 10.1021/acsinfecdis.8b00375.
  • M. J. Mitton-Fry, S. J. Brickner, J. C. Hamel, R. Barham, L. Brennan, J.M. Casavant, X. Ding, S. Finegan, J. Hardink, T. Hoang, M.D. Huband, M. Maloney, A. Marfat, S.P. McCurdy, D. McLeod, C. Subramanyam, M. Plotkin, U. Reilly, J. Schafer, G.G. Stone, D.P. Uccello, T. Wisialowski, K. Yoon, R. Zaniewski, C. ZookNovel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV Bioorg. Med. Chem. Lett., 27:3353-3358, DOI: 10.1016/j.bmcl.2017.06.009.